Hundreds of beautiful and precious treasures: approved as the first line of dual immunotherapy for non-small cell lung cancer in China.

Baisi Mingshi announced that the joint program of Odievo and Yivo has been approved by the Chinese National Medical Products Administration. It is suitable for the first-line treatment of metastatic non-small cell lung cancer with a PD-L1 tumor proportion score greater than 1% approved by the National Medical Products Administration, with epidermal growth factor receptor gene mutation-negative and anaplastic lymphoma kinase-negative. It has become the first approved dual immunotherapy for lung cancer in China.